Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells

Summary Proxalutamide is a newly developed androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (PCa) that has entered phase III clinical trials. In the present study, we intended to elucidate the antitumor efficacy of proxalutamide through the metabolomic prof...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2020-10, Vol.38 (5), p.1292-1302
Hauptverfasser:	Qu, Feng, Gu, Yue, Wang, Qizhi, He, Mingzhe, Zhou, Fang, Sun, Jianguo, Wang, Guangji, Peng, Ying
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen receptors Androgens Anticancer properties Antitumor activity Biotechnology Castration Cell proliferation Cell viability Clinical trials Glutamine Glutathione Glycine Homeostasis Intracellular Intracellular levels Medicine Medicine & Public Health Metabolism Metabolites Metabolomics Oncology Pharmacology/Toxicology Preclinical Studies Prostate cancer Quantitation Receptors Sensitivity enhancement Thymidine Uridine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!